Company intelligence / Profile preview

Aglaia Oncology Funds

Bilthoven, Netherlands

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Aglaia Oncology Funds is a specialized investment firm focused on developing oncology therapies to overcome resistance to targeted cancer treatments. The fund invests in early-stage breakthrough inventions with potential to transform cancer treatment, with a proven track record of transitioning companies to clinical stage.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Investors

Partnerships

Institut CurieGustave RoussyPierre FabreAdvent France BiotechnologyCrédit Mutuel InnovationSinzer (Grant Thornton affiliate)

Beyond the preview

Go deeper on Aglaia Oncology Funds.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aglaia Oncology Funds.

Explore the full profile